These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases. Duan Z; Xu H; Ji X; Zhao J Future Microbiol; 2015; 10(8):1307-23. PubMed ID: 26234909 [TBL] [Abstract][Full Text] [Related]
7. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Speiser DE; Romero P Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326 [TBL] [Abstract][Full Text] [Related]
8. In utero DNA immunisation. Immunity over tolerance in fetal life. Rizzi M; Gerloni M; Srivastava AS; Wheeler MC; Schuler K; Carrier E; Zanetti M Vaccine; 2005 Jul; 23(33):4273-82. PubMed ID: 16005117 [TBL] [Abstract][Full Text] [Related]
10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
11. Engineering vaccines and niches for immune modulation. Purwada A; Roy K; Singh A Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907 [TBL] [Abstract][Full Text] [Related]
12. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. Vergara-Alert J; Argilaguet JM; Busquets N; Ballester M; Martín-Valls GE; Rivas R; López-Soria S; Solanes D; Majó N; Segalés J; Veljkovic V; Rodríguez F; Darji A PLoS One; 2012; 7(7):e40524. PubMed ID: 22815759 [TBL] [Abstract][Full Text] [Related]
13. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers. Takahashi K; Orito N; Tokunoh N; Inoue N Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431 [TBL] [Abstract][Full Text] [Related]
14. Recombinant vaccine delivery systems and encoded vaccines. Stover CK Curr Opin Immunol; 1994 Aug; 6(4):568-71. PubMed ID: 7946044 [TBL] [Abstract][Full Text] [Related]
15. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine. Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737 [TBL] [Abstract][Full Text] [Related]
16. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. Soboleski MR; Gabbard JD; Price GE; Misplon JA; Lo CY; Perez DR; Ye J; Tompkins SM; Epstein SL PLoS One; 2011; 6(7):e21937. PubMed ID: 21789196 [TBL] [Abstract][Full Text] [Related]
18. Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers. Lee Y; Lee YS; Cho SY; Kwon HJ Adv Protein Chem Struct Biol; 2015; 99():75-97. PubMed ID: 26067817 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789 [TBL] [Abstract][Full Text] [Related]
20. Bioconjugate Materials in Vaccines and Immunotherapies. Jewell CM; Caruso F Bioconjug Chem; 2018 Mar; 29(3):571. PubMed ID: 29558810 [No Abstract] [Full Text] [Related] [Next] [New Search]